Clinical advances of dual-pathway antithrombotic therapy in peripheral artery disease
10.3969/j.issn.1008-794X.2025.11.019
- VernacularTitle:双通道抗血栓治疗外周动脉疾病的临床进展
- Author:
Jiuyi SONG
1
;
Nan SHEN
;
Hai WANG
;
Yinteng CHU
;
Ruzhou CAO
;
Qihong NI
;
Yinan LI
;
Lan ZHANG
Author Information
1. 200127 上海 上海交通大学医学院附属仁济医院血管外科
- Keywords:
peripheral artery disease;
revascularization;
dual-pathway antithrombotic therapy;
novel oral anticoagulants
- From:
Journal of Interventional Radiology
2025;34(11):1271-1274
- CountryChina
- Language:Chinese
-
Abstract:
Peripheral artery disease(PAD),commonly encountered in vascular surgery,predominantly affects the lower limbs and presents with ischemic symptoms resulting from atherosclerosis.It carries risks of adverse limb events and cardiovascular events.Antithrombotic therapy remains a cornerstone in the management of PAD.This article reviews the evidence and research progress regarding dual-pathway antithrombotic therapy for PAD.Multiple clinical trials have demonstrated that,compared to single antiplatelet therapy,dual-pathway antithrombotic therapy significantly reduces the risks of major adverse limb events and major adverse cardiovascular events without a significant increase in bleeding risk.For high-risk patients,such as those with advanced age,multivessel disease,comorbid coronary artery disease,or those undergoing endovascular revascularization,the benefits of dual-pathway antithrombotic therapy are particularly pronounced.Current clinical guidelines have incorporated dual-pathway antithrombotic therapy into their recommendations,standardized criteria for identifying the most appropriate patient populations remain lacking.Despite its advantages in reducing adverse events,its long-term safety profile and optimal target populations warrant further investigation.
